Veritas In Silico issued Series 5 stock acquisition rights through a third-party allotment, as well as Series 6 to Series 9 stock acquisition rights, with exercise price adjustment clauses, and entered into a stock acquisition rights purchase agreement.
Veritas In Silico[130A] announced on 13 October 2026 the issuance of Series 5 stock acquisition rights through a third-party allotment and the issuance of Series 6 to Series 9 stock acquisition rights. It also announced that it had entered into a stock acquisition rights purchase agreement. This information was disclosed as timely disclosure.
The Series 5 stock acquisition rights will be issued through a third-party allotment, and it was announced that the Series 6 to Series 9 stock acquisition rights would be issued under the same framework. It was explicitly stated that these rights include exercise price adjustment clauses.
Information on the execution of the purchase agreement was also included in the announcement dated the same day. The text does not include specific terms, amounts or other figures relating to the purchase agreement.